Industry
Neuron23 Inc.
Total Trials
6
Recruiting
1
Active
1
Completed
3
Success Rate
60.0%-27% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
Failure Rate
33.3%
2 terminated/withdrawn out of 6 trials
Success Rate
60.0%
-26.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed trials have results
Key Signals
1 recruiting
Enrollment Performance
Analytics
Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (6)
Showing 6 of 6 trials
NCT06680830Phase 2Recruiting
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Role: lead
NCT06900751Phase 1Completed
A Study to Assess NEU-627 in Healthy Participants
Role: lead
NCT06500442Phase 1Completed
A Study to Assess NEU-111 in Healthy Participants
Role: lead
NCT05755191Phase 1Completed
A Study to Assess NEU-411 in Healthy Participants
Role: lead
NCT04893083Terminated
A Non-interventional Study for the Collection of Biospecimens From Patients With Parkinson's Disease
Role: lead
NCT05633745Phase 1Terminated
A Study to Assess NEU-723 in Healthy Participants
Role: lead
All 6 trials loaded